How to start a GLP-1 telehealth business
The largest category in direct-to-consumer telehealth, and the one where operational detail decides margin. Titration, cold chain and check-in gated refills are where the money is won or lost.
Key takeaways
- GLP-1 is longitudinal care, not a transaction. The business is built on the refill, not the first checkout.
- Titration means the dose changes, so billing has to follow the dose and the ship date, not a calendar.
- Cold chain constrains which pharmacies can fill, which constrains your real state coverage.
- Eligibility screening belongs inside the intake, before payment, or every ineligible patient becomes a refund.
- Check-ins should gate the refill so the provider adjusts before the next shipment goes out.
What you are actually operating
A GLP-1 program is a twelve-month clinical relationship with a shipment attached to it. The patient starts at a low dose, steps up over months as tolerance allows, and reaches a steady state somewhere around month five.
That shape has three operational consequences. The product changes over the patient's life. The refill cadence changes with it. And the patient's most valuable months are the later ones, when acquisition is already paid for, so anything that causes churn in months three to six is disproportionately expensive.
Eligibility, and where the screening runs
Eligibility is commonly screened on BMI thresholds with comorbidity adjustments, alongside contraindication screening covering thyroid and pancreatitis history, current medications and allergies.
The critical design decision is not what you ask but when. Rules that evaluate inside the form stop an ineligible visitor before checkout. Rules that run after payment convert the same person into a refund, a lost processing fee and a dispute risk. In a category processors already treat as high risk, that ratio matters more than the refund does.
Fulfillment: cold chain is a coverage problem
Compounded semaglutide and tirzepatide injectables are temperature-sensitive. Cold chain covers packaging, coolant, transit time and carrier choice, and not every compounding pharmacy is qualified for it.
That means your real coverage for injectables is not your network's state map, it is the cold-chain-qualified subset of it. Operators discover this in week six, having already advertised into states they cannot ship to.
A cold-chain failure is also often silent. The parcel arrives, the patient uses it, and the only symptom is a therapy that appears not to work, surfacing later as churn that gets attributed to the product.
Titration is a billing problem
This is the detail that separates a GLP-1 program that compounds from one that quietly leaks. The dose changes, shipments can be gated by an incomplete check-in, and a pharmacy backorder can delay fulfillment.
A calendar-based subscription charges regardless of all three. It bills for shipments that did not go out, at doses that were not dispensed, which produces disputes.
- Pricing needs to know which dose step the patient is on and how often they are billed.
- Titration steps follow the protocol your providers define, not a fixed ladder.
- The charge goes out when the pharmacy hands the parcel over, not on a date picked in advance.
- What the patient reported at check-in reaches the clinician before they approve the next cycle.
- Multi-month plans bill as fulfillment-timed charges, so a paused patient is not charged.
The visit question
In most states an asynchronous review by a provider licensed in the patient's state is sufficient for an initial GLP-1 prescription. Several states require a synchronous visit first.
Because the list varies and changes, this belongs in the intake rather than in a policy document. GLP-1 runs asynchronously on PharmaBro, so the intake screens state eligibility up front rather than scheduling anything.
Where GLP-1 brands actually lose money
Rarely on price, and rarely on clinical outcomes. The recurring failure modes are operational and they are all fixable.
- Post-payment declines, from screening in the wrong order.
- Involuntary churn, from expired cards on a twelve-month subscription with no account updater coverage.
- Calendar billing, charging for shipments that did not ship.
- Silent cold-chain failures, producing churn that looks like product failure.
- Thin state coverage, spending on traffic in states the network cannot serve.
Built for the refill, not the checkout
PharmaBro routes GLP-1 orders across cold-chain-qualified pharmacies per SKU and state, gates refills on a provider-reviewed check-in, and bills through an in-house rebill engine that fires on the ship date at the dose dispensed.
Zero medication markup and zero revenue share, so you set your own retail price and keep the entire spread. Live in 5 days.
Conclusion
GLP-1 is the most competitive category in the market and the one where infrastructure differences show up fastest, because the therapy is long, the dose moves and the shipment is fragile.
Get three things right and the rest is marketing: screen before you charge, ship cold chain to states you can actually serve, and bill on the fulfillment event at the dose dispensed.
Frequently asked questions
Can a telehealth brand offer compounded semaglutide?
Where clinically appropriate and permitted, prescribed by a provider licensed in the patient's state and dispensed by a licensed compounding pharmacy. Availability is subject to regulatory conditions that change, so patient-facing materials must describe compounded medications accurately.
How often do GLP-1 patients reorder?
Typically every four weeks during titration, extending toward twelve-week cycles once a steady-state dose is reached. Refills should be gated on a check-in so the provider can adjust the dose before the next shipment.
Do GLP-1 patients need a video visit?
Not on PharmaBro. GLP-1 runs fully asynchronously: the patient submits an intake and a licensed provider in their state reviews it. Some states will not permit an async initial prescription, and the intake screens those patients rather than scheduling a call.
What is the biggest operational risk in a GLP-1 brand?
Billing that does not follow the dose and the ship event. It produces charges for shipments that did not go out, which produces disputes, which threatens the merchant account in a category already coded high risk.
Dana WhitfieldDirector of Pharmacy Operations
Runs the pharmacy network and the routing layer. Has negotiated enough fulfillment agreements to have strong opinions about why launches actually slip.